About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...
While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe. The Committee for Medicinal Products for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results